Enzyme replacement therapy in the mouse model of Pompe disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes
Hille-Rehfeld, A. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(95)00004-b · Cited by 249
Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease)
Raben, N., Plotz, P., & Byrne, B. (2002) · Current Molecular Medicine · doi:10.2174/1566524024605789 · Cited by 241
Self-citation
Cited by
van der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease
Fukuda, T., Ewan, L., Bauer, M., Mattaliano, R. J., Zaal, K., Ralston, E., Plotz, P. H., & Raben, N. (2006) · Annals of Neurology · doi:10.1002/ana.20807 · Cited by 303
Self-citationNicolino, M., Byrne, B., Wraith, J. E., Leslie, N., Mandel, H., Freyer, D. R., Arnold, G. L., Pivnick, E. K., Ottinger, C. J., Robinson, P. H., et al. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e31819d0996 · Cited by 293
Kishnani, P. S., Nicolino, M., Voit, T., Rogers, R. C., Tsai, A. C.-H., Waterson, J., Herman, G. E., Amalfitano, A., Thurberg, B. L., Richards, S., et al. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.02.035 · Cited by 282
Self-citationThurberg, B. L., Lynch Maloney, C., Vaccaro, C., Afonso, K., Tsai, A. C.-H., Bossen, E., Kishnani, P. S., & O'Callaghan, M. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700484 · Cited by 261
Self-citationCorti, M., Liberati, C., Smith, B. K., Lawson, L. A., Tuna, I. S., Conlon, T. J., Coleman, K. E., Islam, S., Herzog, R. W., Fuller, D. D., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.146 · Cited by 120
“9 16–21 One potential hypothesis for the limited efficacy of ERT on neuromuscular function is that GAA is not transported across the blood–brain barrier 22,23 and therefore is unlikely to correct the progressive accumulation of glycogen in the central nervous system, especially in neurons.”
Byrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr174 · Cited by 91
Zhang, P., Sun, B., Osada, T., Rodriguiz, R., Yang, X. Y., Luo, X., Kemper, A. R., Clay, T. M., & Koeberl, D. D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.063 · Cited by 88
Han, S.-O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.010 · Cited by 78
Triolo, M., Slavin, M., Moradi, N., & Hood, D. A. (2022) · The Journal of Physiology · doi:10.1113/jp282173 · Cited by 52
Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy
Byrne, B. J., Fuller, D. D., Smith, B. K., Clement, N., Coleman, K., Cleaver, B., Vaught, L., Falk, D. J., McCall, A., & Corti, M. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.56 · Cited by 51
Koeberl, D. D., Case, L. E., Smith, E. C., Walters, C., Han, S.-O., Li, Y., Chen, W., Hornik, C. P., Huffman, K. M., Kraus, W. E., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.023 · Cited by 33
“Type II muscles are resistant to ERT in association with low CI-MPR expression.(5,6) The underlying mechanism for clenbuterol’s effects on muscle was demonstrated as increased expression of insulin-like growth factor (Igf) 1 and 2 and their receptors, including the Igf-2 receptor that is actually CI-MPR.”
BackgroundSelf-citationDesign of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
Metadata
- Authors
- Raben, N., Danon, M., Gilbert, A. L., Dwivedi, S., Collins, B., Thurberg, B. L., Mattaliano, R. J., Nagaraju, K., & Plotz, P. H.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 80
- Issue
- 1-2
- Pages
- 159-169
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2084276666
- Cited by
- 217
- References
- 2
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.